Specialized Protein TFEB May be Key to Understanding LAM
Tuberous Sclerosis Complex (TSC) is a genetic disorder caused by mutations in the TSC1 or TSC2 gene, leading to the hyperactivation of the mechanistic target
Dr. Lyndsay Hoy Appointed Chief Mission Officer of The LAM Foundation
The Board of Directors is pleased and excited to announce the appointment of Dr. Lyndsay Hoy as the inaugural Chief Mission Officer (CMO) of The
LAM Patient Research Priorities Survey Now Open
Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM
Study suggests LAM is more prevalent than previously thought
“Rare diseases are often disregarded given their rarity. Most are underdiagnosed. The minute you tell clinicians that this is actually four to five times more
A Conversation with Vera Krymskaya, PhD, MBA, Scientific Director
Dr. Vera Krymskaya has been appointed Scientific Director at The LAM Foundation after serving as interim since July 2023. She is the first female PhD
LAM Patient Research Priorities Survey Opens in March 2024
Dear LAM Community Members, The LAM Foundation prioritizes supporting LAM scientific research, funding a wide range of projects and initiatives. To maximize impact for LAM
The Latest in LAM Science: Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
The mTORC1 pathway is a signaling pathway in cells in the body that controls cell growth and survival. In many cancers and in LAM, this
The Latest in LAM Science: Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
LAM is caused by changes in some genes that control cell growth called the mTORC1 pathway. Cells use this pathway to make many copies of
This is Where Hope Lives
Google told me I had ten years to live. Ten years. Isaiah turned 10 this year, and he’s only just begun to live a life.
The LAM Foundation Announces Interim Executive Director
On behalf of the Board of Directors of The LAM Foundation, I am thrilled to announce the arrival of Dr. Patricia A. Gentile, Ed.D, as
Statement on Pfizer’s decision on the brand drug, Rapamune, in the U.S.
The LAM Foundation was made aware just yesterday by Pfizer that they will no longer sell or have availability of their brand drug, RAPAMUNE® in
Leadership Change at The LAM Foundation
After a decade of remarkable leadership of the LAM Foundation, Sue Sherman has informed the Board of Directors of her decision to step down from